BRCA1 and breast cancer: Similarly, four of eight patients with metastatic BC carrying BRCA1/2 mutations who were treated with PARPi or platinum developed BRCA reversal mutations, and a significant increase in RAD51 expression after drug resistance was found by detecting changes in protein expression in tumor tissues before and after drug resistance (Waks et al., 2020).